TerminatedPhase 2NCT00084461

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Studying Zollinger-Ellison syndrome

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Manisha Shah
Ohio State University
Intervention: romidepsin(drug)
Enrollment: 25 enrolled
Eligibility: 18 years · All sexes
Timeline: 2004

Study locations (1)

Ohio State University Medical Center, Columbus, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00084461 on ClinicalTrials.gov

Other trials for Zollinger-Ellison syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT01824875
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
ECOG-ACRIN Cancer Research Group

See all trials for Zollinger-Ellison syndrome →

← Back to all trials